Canada Life’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-109,938
| Closed | -$414K | – | 2841 |
|
|
2020
Q1 | $414K | Hold |
109,938
| – | – | ﹤0.01% | 1659 |
|
|
2019
Q4 | $555K | Buy |
+109,938
| New | +$582K | ﹤0.01% | 1685 |
|
|
2019
Q3 | – | Sell |
-115,665
| Closed | -$712K | – | 2653 |
|
|
2019
Q2 | $712K | Hold |
115,665
| – | – | ﹤0.01% | 1670 |
|
|
2019
Q1 | $538K | Hold |
115,665
| – | – | ﹤0.01% | 1608 |
|
|
2018
Q4 | $447K | Buy |
115,665
+16,707
| +17% | +$85.1K | ﹤0.01% | 1711 |
|
|
2018
Q3 | $619K | Hold |
98,958
| – | – | ﹤0.01% | 1683 |
|
|
2018
Q2 | $795K | Hold |
98,958
| – | – | ﹤0.01% | 1616 |
|
|
2018
Q1 | $736K | Hold |
98,958
| – | – | ﹤0.01% | 1616 |
|
|
2017
Q4 | $587K | Hold |
98,958
| – | – | ﹤0.01% | 1687 |
|
|
2017
Q3 | $722K | Sell |
98,958
-8,400
| -8% | -$53.4K | ﹤0.01% | 1630 |
|
|
2017
Q2 | $728K | Buy |
107,358
+6,800
| +7% | +$50.2K | ﹤0.01% | 1615 |
|
|
2017
Q1 | $948K | Buy |
100,558
+88,358
| +724% | +$882K | ﹤0.01% | 1529 |
|
|
2016
Q4 | $106K | Hold |
12,200
| – | – | ﹤0.01% | 2103 |
|
|
2016
Q3 | $77K | Hold |
12,200
| – | – | ﹤0.01% | 2236 |
|
|
2016
Q2 | $51K | Hold |
12,200
| – | – | ﹤0.01% | 2305 |
|
|
2016
Q1 | $53K | Hold |
12,200
| – | – | ﹤0.01% | 2102 |
|
|
2015
Q4 | $75K | Hold |
12,200
| – | – | ﹤0.01% | 1956 |
|
|
2015
Q3 | $70K | Buy |
+12,200
| New | +$93.6K | ﹤0.01% | 1935 |
|
Other funds holding PGNX
Canada Life's PGNX Position: Q2 2020 in Review
Canada Life sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 109,938 shares — an estimated $414K sold.
Canada Life first reported a position in PGNX in Q3 2015 and held it in 18 quarters. The position peaked at $948K in Q1 2017. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.
- Canada Life reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
- Canada Life sold 109,938 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $414K.
- Canada Life first reported a position in Progenics Pharmaceuticals Inc in Q3 2015 and held it in 18 quarters.
- Canada Life's Progenics Pharmaceuticals Inc position peaked at $948K in Q1 2017.
- 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.
Based on Canada Life's 13F filing for Q2 2020, filed 17 Aug 2020.